Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Clinical Medicine Insights. Oncology
|
August 12, 2022
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
Minal Barve, Phylicia Aaron, Luisa Manning, et al.
Cancer Gene Therapy
|
November 17, 2021
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
Elyssa Sliheet, Molly Robinson, Susan Morand, et al.
Vaccines
|
October 26, 2021
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
Vedin Barve, Ned Adams, Laura Stanbery, et al.
Scientific Reports
|
March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
David Willoughby, Ernest Bognar, Laura Stanbery, et al.
The Journal of Gene Medicine
|
May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety
Christopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Cancers
|
December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response
John Nemunaitis, Laura Stanbery, David Willoughby, et al.
Future Science OA
|
March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy
Fabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Gynecologic Oncology
|
November 15, 2024
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer
Manoj Sonavane, Jenna Hedlich-Dwyer, Valeria L Dal Zotto, et al.
Vaccines
|
August 28, 2021
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
Rodney P Rocconi, Laura Stanbery, Luciana Madeira da Silva, et al.
Gynecologic Oncology Reports
|
June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]
Jonathan Oh, Minal Barve, Neil Senzer, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Clinical Medicine Insights. Oncology
|
August 12, 2022
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
Minal Barve, Phylicia Aaron, Luisa Manning, et al.
Cancer Gene Therapy
|
November 17, 2021
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
Elyssa Sliheet, Molly Robinson, Susan Morand, et al.
Vaccines
|
October 26, 2021
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
Vedin Barve, Ned Adams, Laura Stanbery, et al.
Scientific Reports
|
March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
David Willoughby, Ernest Bognar, Laura Stanbery, et al.
The Journal of Gene Medicine
|
May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety
Christopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Cancers
|
December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response
John Nemunaitis, Laura Stanbery, David Willoughby, et al.
Future Science OA
|
March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy
Fabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Gynecologic Oncology
|
November 15, 2024
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer
Manoj Sonavane, Jenna Hedlich-Dwyer, Valeria L Dal Zotto, et al.
Vaccines
|
August 28, 2021
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
Rodney P Rocconi, Laura Stanbery, Luciana Madeira da Silva, et al.
Gynecologic Oncology Reports
|
June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]
Jonathan Oh, Minal Barve, Neil Senzer, et al.
Page
of 2